Steve Brozak
Stock Analyst at WBB Securities
(0.47)
# 4,295
Out of 5,239 analysts
9
Total ratings
33.33%
Success rate
-14.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Brozak
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMER Omeros | Reiterates: Strong Buy | $45 | $14.76 | +204.88% | 3 | Oct 15, 2025 | |
| CELU Celularity | Upgrades: Buy | $6 | $0.78 | +672.70% | 2 | Sep 9, 2025 | |
| MRKR Marker Therapeutics | Reiterates: Strong Buy | $13 | $1.44 | +768.06% | 1 | Apr 1, 2025 | |
| RDHL RedHill Biopharma | Downgrades: Buy | $17,000 → $16,000 | $1.02 | +1,568,527.45% | 3 | May 28, 2021 |
Omeros
Oct 15, 2025
Reiterates: Strong Buy
Price Target: $45
Current: $14.76
Upside: +204.88%
Celularity
Sep 9, 2025
Upgrades: Buy
Price Target: $6
Current: $0.78
Upside: +672.70%
Marker Therapeutics
Apr 1, 2025
Reiterates: Strong Buy
Price Target: $13
Current: $1.44
Upside: +768.06%
RedHill Biopharma
May 28, 2021
Downgrades: Buy
Price Target: $17,000 → $16,000
Current: $1.02
Upside: +1,568,527.45%